Morning Overview on MSN

Researchers find some cancer drugs work differently than their stated targets

As of spring 2026, a cancer drug that has spent years in clinical development as a Wnt/beta-catenin pathway blocker has been ...
Morningstar

Parabilis Medicines’ Zolucatetide, the First and Only Direct Inhibitor of the Elusive β-catenin:TCF Interaction, Receives FDA Orphan Drug Designation for the Treatment of ...

Parabilis Medicines’ Zolucatetide, the First and Only Direct Inhibitor of the Elusive β-catenin:TCF Interaction, Receives FDA Orphan Drug Designation for the Treatment of Desmoid Tumors Latest ...
Business Wire

Parabilis Medicines Highlights Promising Preliminary Clinical Results in Patients with Adamantinomatous Craniopharyngioma from Ongoing FOG-001 Clinical Trial at SNO 2025

Consistent, significant tumor reductions across all ACP patients mark the second low-complexity Wnt/β-catenin-driven tumor subgroup – alongside desmoid tumors – showing uniform monotherapy activity in ...
Cure Today

FDA Fast Tracks FOG-001 After Early Tumor Shrinkage in Desmoid Tumors

FOG-001 targets the β-catenin–TCF interaction, a previously "undruggable" target, offering new hope for desmoid tumor treatment. Early clinical trials show FOG-001 leads to significant tumor shrinkage ...
Nature

Betting on β-catenin inhibitors in oncology

A long list of drug targets are deemed undruggable, beyond the reach of current drug discovery technologies. A few companies hope to soon cross the β-catenin transcription factor off that list.
Morningstar

Parabilis Medicines Reports Early Clinical Evidence that Zolucatetide Reduces Polyp Burden in a Patient with Familial Adenomatous Polyposis

Preliminary clinical data presented at the InSiGHT Biennial Meeting demonstrate significant reductions in duodenal polyposis and the size of the co-existing desmoid tumor in a patient from the ongoing ...